Clinical Trial Update: Imatinib Mesylate (Gleevec) and Docetaxel in Patients With Head and Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of Imatinib Mesylate (Gleevec) and Docetaxel in patients with head and neck squamous cell carcinoma has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Gleevec (Imatinib)
• Taxotere (docetaxel)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Head and Neck Cancer, Squamous Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2011-08-29